NCT06833255 A Post-treatment Supportive Service Program for the Transition Into Survivorship for Black Women Breast Cancer Survivors in Western New York
| NCT ID | NCT06833255 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Roswell Park Cancer Institute |
| Condition | Breast Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 125 participants |
| Start Date | 2025-04-21 |
| Primary Completion | 2030-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 125 participants in total. It began in 2025-04-21 with a primary completion date of 2030-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial studies whether a post-treatment supportive service program can be used to help breast cancer survivors in Western New York (WNY) transition into post-treatment life (survivorship). The post-treatment supportive service program is delivered to breast cancer survivors of WNY. It combines group support sessions and one-on-one (1:1) peer mentoring sessions. The group support sessions include traditional support groups, educational topics/lessons, activities, such as cooking lessons, celebrations, or facility tours, and guest speakers. The 1:1 peer mentoring sessions are held with a long-term breast cancer survivor mentor. The long-term breast cancer survivor mentor helps the mentee get in the practice of performing once monthly self-assessments and create plans to help improve any identified modifiable risk factors. The long-term breast cancer survivor mentor can also help connect the mentee to providers or resources as needed. A post-treatment supportive service program may help Black women breast cancer survivors in WNY transition into survivorship.
Eligibility Criteria
Inclusion Criteria: * Ability to speak and read English * At least 18 years of age or older * Live in the Western New York area * Has been diagnosed with breast cancer (any stage) * Has completed primary breast cancer treatments (i.e., systemic, radiation, and/or surgical interventions other than breast reconstruction surgeries) * Mentors are at least one-year post-treatment completion * Mentees are less than one-year post-treatment completion * Note: Individuals who have completed primary breast cancer treatments who are being managed with ongoing hormonal therapies and/or are awaiting breast reconstruction surgery may participate in this study (i.e., these therapies do not meet exclusion criteria) * Note: Although any breast cancer survivor may participate, priority will be given to those who have most recently transitioned into their post-treatment life (or those who report that support was either not offered or was unavailable to them during their less recent transition into post-treatment life) and /or self-identify as African American Exclusion Criteria: * Currently receiving neoadjuvant and/or adjuvant systemic and/or radiations therapies * Unwilling or unable to complete the assessment in English * Are pregnant or nursing * Are unwilling or unable to follow protocol requirements * Note: Individuals who have completed primary breast cancer treatments who are being managed with ongoing hormonal therapies and/or are awaiting breast reconstruction surgery may participate in this study (i.e., these therapies do not meet exclusion criteria)
Contact & Investigator
Julia Devonish
PRINCIPAL INVESTIGATOR
Roswell Park Cancer Institute
Frequently Asked Questions
Who can join the NCT06833255 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06833255 currently recruiting?
Yes, NCT06833255 is actively recruiting participants. Visit ClinicalTrials.gov or contact Roswell Park Cancer Institute to inquire about joining.
Where is the NCT06833255 trial being conducted?
This trial is being conducted at Buffalo, United States.
Who is sponsoring the NCT06833255 clinical trial?
NCT06833255 is sponsored by Roswell Park Cancer Institute. The principal investigator is Julia Devonish at Roswell Park Cancer Institute. The trial plans to enroll 125 participants.